Verici Dx Plc (GB:VRCI) has released an update.
Verici Dx Plc has announced the successful completion of a urine sample transfer to Thermo Fisher Scientific, a step in the global commercialization and licensing agreement from November 2023. The company, specializing in advanced diagnostics for organ transplant, has received full payment for the transfer, underscoring the value of its data and sample assets for research. CEO Sara Barrington expressed satisfaction with the company’s adherence to timelines and the demonstration of its commitment to agreements.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
